Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13G Filing: Biotechnology Value Fund LP and Alpine Immune Sciences Inc. (ALPN)

Published on July 28, 2017 at 2:54 pm by Insider Monkey Staff in Hedge Funds

Page 1 of 13

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Biotechnology Value Fund	0		0	277,314	277,314	2.0%
Biotechnology Value Fund II	0		0	179,272	179,272	1.3%
Biotechnology Value Trading Fund OS	0		0	50,452	50,452	Less%
BVF Partners OS Ltd	0		0	50,452	50,452	Less%
BVF Partners	0		0	661,200	661,200	4.8%
BVF Inc	0		0	661,200	661,200	4.8%
Mark N. Lampert	0		0	661,200	661,200	4.8%

Page 1 of 13 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 3)¹

Alpine Immune Sciences, Inc. (formerly known as Nivalis Therapeutics, Inc.)

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

02083G100

(CUSIP Number)

July 24, 2017

(Date of Event Which Requires Filing of this
Statement)

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 13

NASDAQ:ALPN SEC 13G Filing Biotechnology Value Fund L P Alpine Immune Sciences Inc. (ALPN)